Drug maker Amgen announced today that it has reached a global settlement with AbbVie, developer of reference adalimumab (Humira), over Amgen’s biosimilar adalimumab, Amgevita.
Drug maker Amgen announced today that it has reached a global settlement with AbbVie, developer of reference adalimumab (Humira), over Amgen’s biosimilar adalimumab, Amgevita.
Under the agreement, AbbVie will grant patent licenses to Amgen for the sale of its drug on a country-by-country basis. As part of the settlement, the companies have dismissed all pending litigation over the drug.
Neither company disclosed the financial terms of the agreement, but Amgen indicated that it will launch its drug, to be marketed as Amgevita, in the European Union on October 16, 2018. In the United States, the biosimilar will be marketed under a slightly different name—Amjevita—and will launch on January 31, 2023.
"We look forward to leveraging our existing biologics capabilities to bring high-quality biosimilars to patients worldwide. [Amgevita] will be one of our first biosimilar launches, and this agreement will allow us to secure a strong foothold in the $4 billion European adalimumab market," said Scott Foraker, vice president and general manager of biosimilars at Amgen.
The FDA approved Amgen’s biosimilar drug in September 2016, and the European Commission authorized its marketing in March 2017. However, litigation over AbbVie’s patents for the innovator Humira had made it unclear when the biosimilar would become commercially available. AbbVie had sued Amgen for infringing on 10 of its patents covering adalimumab.
News of today’s settlement raises questions as to whether a similar agreement could be forthcoming for AbbVie and Boehringer Ingelheim (BI), which saw its own biosimilar adalimumab, Cyltezo, approved by the FDA in August and recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use earlier this month.
In Cyltezo’s case, AbbVie filed an even more extensive lawsuit against BI, saying that BI would infringe on 74 patents. The first phase of BPCIA litigation over Cyltezo’s alleged infringement will involve 8 of those patents, as BI did not consent to AbbVie’s proposal of a single wave of patent litigation.
The reference Humira is the top selling drug in the world, earning AbbVie $16.08 billion in 2016. While its global sales grew by 14.7% last year, biosimilar competition and the introduction of new drugs are expected to erode its dominance in the rheumatoid arthritis and inflammatory disease marketplace.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.